Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma

Cancer Letters

Volumn 193, Issue 1, 2003, Pages 75-81

  Jalbout, Majida ^a   Bouaouina, Noureddine ^a,b   Gargouri, Jalel ^c   Corbex, Marilys ^d   Ahmed, Slim Ben ^b   Chouchane, Lotfi ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c UNIVERSITY OF SFAX   (Tunisia)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Nasopharyngeal carcinoma; Stress protein; Tumor necrosis factor

Indexed keywords

HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 2; RESTRICTION ENDONUCLEASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 0037431043     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00697-3     Document Type: Article

References (42)

1. Parkin D., Whelan S., Ferlay J., Raymond L., Young J. Cancer Incidence in Five Continents. 1997;IARC Scientific Publications, Lyon. p. 143.
2. Parkin D., Kramarova E., Draper G., Masuyer E., Michaelis J., Neglia J. International Incidence of Childhood Cancer. 1998;IARC Scientific Publications, Lyon. p. 144.
3. Stiller C.A. International variations in the incidence of childhood carcinomas. Cancer Epidemiol. Biomarkers Prev. 3:1994;305-310.
4. Jeannel D., Bouvier G., Hubert A. Nasopharayngeal Carcinoma: an Epidemiological Approach to Carcinogenesis. Infection and Human Cancer. Cancer Surveys. 33:1999;. (Imperial Cancer Research Fund, UK).
5. Hildesheim A., Levine P.H. Etiology of nasopharyngeal carcinoma: a review. Epidemiol. Rev. 15:1993;466-485.
6. Goldsmith D.B., Morton T.M., West R. HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta analysis. Clin. Otolaryngol. 27:2002;61-67.
7. Dardari R., Khyatti M., Jouhadi H., Benider A., Ettayebi H., Kahlain H., Mansouri A., El Gueddari B., Benslimane A. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int. J. Cancer. 92:2001;294-297.
8. Mokni-Baizig N., Ayed K., Ayed F.B., Ayed S., Sassi F., Ladgham A., Bel Hadj O., El May A. Association between HLA-A/-B antigens and-DRB1 alleles and nasopharyngeal carcinoma in Tunisia. Oncology. 61:2001;55-58.
9. Burt R.D., Vaughan T.L., McKnight B., Davis S., Beckmann A.M., Smith A.G., Nisperos B., Swanson G.M., Berwick M. Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol. Biomarkers Prev. 5:1996;879-887.
10. Daniilidis M., Fountzilas G., Fleva A., Daniilidis J., Tourkantonis A. Haplotypes of human leukocyte antigens among patients with nasopharyngeal cancer in Greece. Oncology. 54:1997;185-192.
11. Lu S.J., Day N.E., Degos L. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature. 346:1990;470-471.
12. Ooi E.E., Ren E.C., Chan S.H. Association between microsatellites within the human MHC and nasopharyngeal carcinoma. Int. J. Cancer. 74:1997;229-232.
13. Tracey K.J. TNF and Mae West or: death from too much of a good thing. Lancet. 345:1995;75-76.
14. Gadducci A., Ferdeghini M., Castellani C., Annicchiarico C., Gagetti O., Prontera C., Bianchi R., Facchini V. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55 and 75 kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol. Oncol. 58:1995;184-188.
15. Partanen R., Koskinen H., Hemminki K. Tumor necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer. Occup. Environ. Med. 52:1995;316-319.
16. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1996;1717-1725.
17. Barnes P.J., Karin M. Nuclear factor Kappa B: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1996;1066.
18. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M.C., Rieux C., Coiffier B. Elevated circulating levels of TNF- and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br. J. Haematol. 93:1996;352-359.
19. Warzocha K., Salles G., Bienvenu J., Bastion Y., Dumontet C., Renard N., Neidhardt-Berard E.M., Coiffier B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 15:1997;499-508.
20. Tracey K.J., Wei H., Manogue K.R., Fong Y., Hess D.G., Nguyen H.T., Kuo G.C., Beutler B., Cotran R.S., Cerami A. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J. Exp. Med. 167:1988;1211-1227.
21. Himeno T., Watanabe N., Yamauchi N., Maeda M., Tsuji Y., Okamoto T., Neda H., Niitsu Y. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res. 50:1990;4941-4945.
22. Okamoto T., Watanabe N., Yamauchi N., Tsuji N., Itoh Y., Neda H., Niitsu Y. Endogenous tumor necrosis factor exert its protective function intracellulary against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res. 52:1992;5278-5281.
23. Tsuji Y., Watanabe N., Okamoto T., Tsuji N., Sasaki H., Akiyama S., Yamauchy N., Niitsu Y. Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity. Cancer Res. 52:1992;6258-6262.
24. Fujiki H., Komori A., Yatsunami J. Tumor necrosis factor as an endogenous tumor promotor. Proc. Am. Assoc. Cancer Res. 34:1993;180.
25. Fujiki H., Suganuma M., Komori A., Yatsunami J., Okabe S., Ohta T., Sueoka E. A new tumor promotion pathway and its inhibitors. Cancer Detect. Prev. 18:1994;1-7.
26. Wilson A.G., Di Giovine F.S., Balkemore A.I.F., Duff G.W. Single base polymorphism in the human tumor necrosis factor alpha (TNF) gene detectable by Nco1 restriction of PCR product. Hum. Mol. Genet. 1:1993;353-359.
27. Wilson A.G., SymonsMc J.A., Dowell T.L., Di Giovine F.S., Duff G.W. Effects of a tumor necrosis factor (TNF-alpha) promotor base transition on transcriptional activity. Br. J. Rheumatol. 33:1994;89-97.
28. Sargent C.A., Dunham I., Trowsdale J., Campbell R.D. Human major histocompatibility complex contains genes for the major heat shock protein HSP70. Proc. Natl Acad. Sci. USA. 86:1989;1968-1972.
29. Milner C.M., Campbell R.D. Structure and expression of the MHC-linked HSP70 genes. Immunogenetics. 32:1990;242-251.
30. Hunt C., Morimoto R.I. Conserved features of eukaryotic HSP70 genes revealed by comparison with the nucleotide sequence of human HSP70. Proc. Natl Acad. Sci. USA. 82:1985;6455-6459.
31. Van buskirk A.M., De Nagel D.C., Gualiardim L.E. Cellular and subcellular distribution of PBP 72/74, a peptide-binding proteins that plays a role in antigen processing. J. Immunol. 146:1991;500-506.
32. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned-peptides. Science. 269:1995;1585-1588.
33. Soti C., Csermely P. Molecular chaperones in the etiology and therapy of cancer. Pathol. Oncol. Res. 4:1998;316-321.
34. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 39:1992;225-235.
35. Cabrera M., Shaw M.A., Sharples C., Williams H., Casres M., Convit J., Blackwell J.M. Polymorphism in tumor necrosis factor genes associated with muocutaneous leishmaniasis. J. Exp. Med. 182:1995;1259-1264.
36. Milner C.M., Campbell R.D. Polymorphic analysis of the three MHC-linked HSP70 genes. Immunogenetics. 36:1992;357-362.
37. Sham P.C., Curtis D. Monte Carlo tests for association between diseases and alleles at highly polymorphic loci. Ann. Hum. Genet. 59:1995;97-105.
38. J.H. Zhao, http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/GEpiBSt/software.stm.
39. Souhir M., Bouaouina N., Ben Ahmed S., Khedaier A., Jrad B.B., Remadi S., Chouchane L. Genetic variation in the tumor necrosis factor-α promoter region and in the stress protein HSP70-2: susceptibility and prognostic implications in breast carcinoma. Cancer. 91:2001;672-678.
40. Rippmann F., Taylor W.R., Rothbard J.B., Green N.M. A hypothetical model for the peptide binding domain of HSP70 based on the peptide binding domain of HLA. EMBO J. 10:1991;1053-1059.
41. Punyiczki M., Fésus L. Heat shock and apoptosis: the two defense systems of the organisms may have overlapping molecular elements. Ann. NY Acad. Sci. 851:1998;67-74.
42. Jäattelä M. Overexpression of major heat shock protein HSP70 inhibits tumor necrosis factor-induced activation of phospholipase A2. J. Immunol. 151:1993;4286-4294.